ClinicalTrials.gg
CompletedNCT07001579Updated Jun 3, 2025

Cross-sectional Study of the Prevalence and Risk Factors of Asymptomatic Bacteriuria in Pregnancy

An observational study in Urinary Tract Infection (Diagnosis) and Pregnancy, sponsored by Nepalese Army Institute of Health Sciences. Completed at 1 site in Nepal. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Nepalese Army Institute of Health Sciences · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
390
Ages
18 Years and older
Sex
Female
01

Study summary

Asymptomatic bacteriuria (ASB) is the presence of bacteria in the urine without symptoms of urinary tract infection. It is common during pregnancy and, if left untreated, may lead to complications such as pyelonephritis, preterm labor, and low birth weight. This cross-sectional study aims to determine the prevalence and identify associated risk factors of ASB among pregnant women attending antenatal care at a tertiary care hospital. Pregnant women meeting the inclusion criteria will be enrolled and evaluated through urine analysis and relevant history-taking. The findings may help guide future screening and treatment policies in antenatal care settings

02

Conditions studied

  • Urinary Tract Infection (Diagnosis)
  • Pregnancy
03

In context

Urinary Tract Infections

803 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

This study's enrollment of 390 is above the median of 236 across 198 observational studies indexed under Urinary Tract Infections.

Browse Urinary Tract Infections studies →

Lead sponsor

Nepalese Army Institute of Health Sciences is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women visiting the Department of Obstetrics and Gynecology OPD, (Shree Birendra Hospital) located in Kathmandu for Antenatal Check-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women attending her regular ANC check-ups at the hospital.
  • Who give consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Individuals not willing to participate
  • Pregnant women showing signs and symptoms of UTI.
  • Pregnant women on antibiotics or had been on antibiotics at least two weeks prior to presentation.
  • Pregnant women with known underlying renal pathology.
  • Pregnant women who are using immune-suppressants.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
390 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence of Asymptomatic Bacteriuria in Pregnant Women

    The proportion of pregnant women attending antenatal care who test positive for asymptomatic bacteriuria based on urine culture

    Time frame: Data was collected for 6 months after approval from IRC from April 2022 to September 2022 during each participant's first antenatal care (ANC) visit irrespective of the gestational age, using simple convenient sampling method.

07

Study locations

1 site
  • Shree Birendra Hospita
    Kathmandu, Bagmati 44600, Nepal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Mar 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
Jun 3, 2025
StartActual
Apr 1, 2022
Primary completionActual
Mar 14, 2023
CompletionActual
Aug 26, 2024
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07001579
Lead sponsor
Nepalese Army Institute of Health Sciences
Responsible party
Sabin Poudel (Dr., Nepalese Army Institute of Health Sciences) — Principal investigator
First posted
Jun 3, 2025
Start date
Apr 1, 2022
Primary completion
Mar 14, 2023
Completion
Aug 26, 2024
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion